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ttp://dx.doi.org/10.1016/j.ajpath.2013.12.023Clinical and animal studies implicate erythropoietin (EPO) and EPO receptor (EPOR) signaling in angio-
genesis. In the eye, EPO is involved in both physiological and pathological angiogenesis in the retina. We
hypothesized that EPOR signaling is important in pathological angiogenesis and tested this hypothesis
using a rat model of oxygen-induced retinopathy that is representative of human retinopathy of prema-
turity.Weﬁrst determined that EPOR expression and activationwere increased and that activated EPORwas
localized to retinal vascular endothelial cells (ECs) in retinas at postnatal day 18 (p18), when pathological
angiogenesis in the form of intravitreal neovascularization occurred. In human retinal microvascular ECs,
EPORwas up-regulated and activated by VEGF. Lentiviral-delivered shRNAs that knocked downMüller celle
expressed VEGF in the retinopathy of prematurity model also reduced phosphorylated EPOR (p-EPOR) and
VEGFR2 (p-VEGFR2) in retinal ECs. In human retinal microvascular ECs, VEGFR2-activated EPOR caused an
interaction between p-EPOR and p-VEGFR2; knockdown of EPOR by siRNA transfection reduced VEGF-
induced EC proliferation in associationwith reduced p-VEGFR2 and p-STAT3; however, inhibition of VEGFR2
activation by siRNA transfection or semaxanib (SU5416) abolished VEGFA-induced proliferation of ECs
and phosphorylation of VEGFR2, EPOR, and STAT3. Our results show that VEGFA-induced p-VEGFR2 acti-
vates EPOR and causes an interaction between p-EPOR and p-VEGFR2 to enhance VEGFA-induced EC pro-
liferation by exacerbating STAT3 activation, leading to pathological angiogenesis. (Am J Pathol 2014,
184: 1230e1239; http://dx.doi.org/10.1016/j.ajpath.2013.12.023)Supported by NIH grants R01-EY015130 and R01-EY017011 (M.E.H.),
March of Dimes grant 6-FY13-75 (M.E.H.), and an unrestricted grant from
Research to Prevent Blindness, Inc., to the Department of Ophthalmology
& Visual Sciences, University of Utah.
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Disclosures: None declared.Retinopathy of prematurity (ROP) is an important cause of
vision loss and blindness in infants worldwide.1 Because of
the limited ability to study human preterm infant eyes,
models have been established in which newborn animals
that normally vascularize their retinas after birth are exposed
to oxygen stresses that lead to retinal features similar to
human ROP.2 Based on such models of oxygen-induced
retinopathy (OIR) and on observations in human infants,
ROP has been described as having two phases.3,4 In phase I,
infants experience delayed physiological retinal vascular
development and sometimes vasoattenuation from high
oxygen.5 Phase II is characterized by aberrant disordered
developmental angiogenesis in the form of vasoproliferative
intravitreal neovascularization (IVNV).2 Several angiogenic
agonists and inhibitors have been recognized as potentially
involved in human ROP. Of these, the most studied is
vascular endothelial growth factor A (VEGFA).6e9
Besides being involved in human pathological angiogenic
eye disease,10 VEGFA is also important in retinal vascularstigative Pathology.
.development.11,12 Inhibition of the bioactivity of VEGFA in
preterm infants with severe ROP reduced the IVNV of phase
II,13 but reports of persistent avascular retina and recurrent
pathological angiogenesis raised concern.14 Furthermore,
neutralizing VEGFA with an antibody similar to that used in
human preterm infants with severe ROP initially reduced
IVNV in the rat ROPmodel, but caused recurrent pathological
angiogenesis in association with up-regulation of several
angiogenic agonists, including erythropoietin (EPO).15
EPO is known mainly for hematopoiesis, and it has been
used to treat anemia.16 However, a growing body of evidence
indicates that EPO has other biological effects, including
neuroprotective,17e19 antiapoptotic,19,20 antioxidative,20,21
VEGFA Activates EPOR in Angiogenesisand angiogenic22e24 properties. Evidence supporting the role
of EPO in angiogenesis comes from clinical and animal
studies. In clinical studies, proliferative diabetic retinopathy
and severe ROP have been associated with increased EPO. In
proliferative diabetic retinopathy, vitreous EPO was
increased,25 and a promoter polymorphism in the EPO gene
resulting in increased production of EPO was associated with
severe diabetic retinopathy in a largely European-American
population.26 In ROP, greater risk of severe ROP was asso-
ciated with EPO treatment for anemia of prematurity.27,28 In a
mouse OIR model, hyperoxia down-regulated EPO expres-
sion in the retina and decreased vascular stability in associa-
tionwith vaso-obliterated retina,29 and, after relative hypoxia,
retinal EPO was increased and contributed to IVNV.30 EPO
was also identiﬁed as a target in OIR in a study using a
transgenic mouse in which hypoxia inducible factor 2a
(HIF-2a; EPAS1, alias HLF) was knocked down,31 and EPO
synergistically increased VEGFA-induced human retinal
microvascular endothelial cell (hRMVEC) proliferation.15
However, EPO also promoted physiological retinal vascu-
larization in a rat OIRmodel.32 Thus, the evidence ismixed, in
that EPO has been associated with both physiological and
pathological retinal angiogenesis. EPO is now being consid-
ered as a neuroprotective agent to promote cognitive devel-
opment in preterm infants.33 Greater understanding is needed
regarding EPO and EPO receptor (EPOR) signaling in ROP
and developmental angiogenesis.
In the present study, we used a rat ROP model34 in which
VEGFA is overexpressed by postnatal day 12 (p12) and
causes IVNV at p18.35 Our research group previously found
that the VEGFA signal is detected in Müller cells and
developed a method using a lentiviral vector that targets
Müller cells and knocks down VEGFA in vivo, thereby
inhibiting IVNV without interfering with pup growth or
serum VEGFA.36 The present investigation of the role of
EPOR adapted lentiviral vector rat model. In phase I, EPOR
activation was lower than in phase II, when VEGFA
expression and VEGFR2 expression and activation were
increased.37 In hRMVECs, VEGFA up-regulated and acti-
vated EPOR and (through crosstalk between activated
VEGFR2 and EPOR) increased the activation of STAT3 to
enhance angiogenesis. Our present ﬁndings support the
hypothesis that VEGFA activates and causes an interaction




The rat ROP model used in this study has been described
previously.34 Within 6 hours of birth, newborn Spra-
gueeDawley pups and dam (Charles River Laboratories
International, Wilmington, MA) were placed into a regu-
lated oxygen environment (OxyCycler; BioSpherix, Lacona,
NY) in which oxygen was cycled between 50% and 10%The American Journal of Pathology - ajp.amjpathol.orgevery 24 hours for 14 days, and then into ambient room air
(RA) for 4 days. Phase I, delayed physiological retinal
vascular development, occurred at p14 and phase II, IVNV,
at p18. All animal studies were performed in compliance
with the University of Utah (incorporating the current Guide
for the Care and Use of Laboratory Animals) and the As-
sociation for Research in Vision and Ophthalmology
Statement for the Use of Animals in Ophthalmic and Visual
Research. For each study, at least three different litters were
analyzed for immunohistochemistry, quantitative real-time
PCR (qPCR), or Western blotting; all litters had between
12 and 14 pups.
For knockdown of Müller cell VEGFA, we used a
lentivirus with a CD44 promoter that drives GFP and
VEGFA shRNA when embedded within a microRNA 30
context. A subretinal injection of 1 mL of lentivirus (1  109
viral particles per milliliter) with either VEGFA shRNA or
control luciferase shRNA was delivered at the beginning of
the 50% oxygen cycle of the ROP model, on p8, as
described previously.36 Each pup received the same type of
lentivector in each eye, to reduce the potential for con-
founding from crossover effects. Eyes were processed for
immunohistochemistry of phosphorylated VEGFR2 (p-
VEGFR2), or EPOR (p-EPOR) and lectin.
Retinal Section Preparation and Staining
Anterior segments were removed from eyes after 10 minutes
of ﬁxation in 4% paraformaldehyde (Electron Microscopy
Sciences, Hatﬁeld, PA); retinas were carefully dissected and
placed into 4% paraformaldehyde for another 15 minutes,
followed by overnight incubation in 30% sucrose. After
immersion in optimal cutting temperature compound
[Tissue-Tek OCT (Sakura Finetek, Torrance, CA); Electron
Microscopy Sciences, Hatﬁeld, PA], retinas were cut into 12-
mm cryosections. Sections were incubated with rabbit
antiep-VEGFR2 (1:50; Abcam, Cambridge, MA) or antiep-
EPOR (1:50; Santa Cruz Biotechnology, Dallas, TX) over-
night at 4C. After rinsing, sections were incubated for 1 hour
with FITC-conjugated goat anti-rabbit secondary antibody
(1:200; Jackson ImmunoResearch Laboratories, West Grove,
PA.) and Alexa Fluor 594econjugated antibody for isolectin
B4 (lectin) (1:500; Life Technologies, Carlsbad, CA), to stain
vessels. Sections stained without primary antibodies were
used as controls. Labeling for all sections was performed
during the same experiment session. Images were captured
using confocal microscopy (Olympus IX81; Olympus,
Tokyo, Japan) at 20 or 40 magniﬁcation.
Cell Culture, Transfection, and Proliferation Assay
hRMVECs (Cell Systems, Kirkland, WA) were maintained
in EGM-2 endothelial growth medium (Lonza, Walkers-
ville, MD) supplemented with 5% fetal bovine serum. Cells
of passage 3 to 5 were used for experiments. Conﬂuent cells
in six-well plates were starved for 16 hours and then treated1231
Yang et alwith 20 ng/mL VEGFA or PBS for 24 hours for qPCR or
were treated with VEGFA for 30 minutes for p-VEGFR2,
p-EPOR, and p-STAT3.
For siRNA transfection, hRMVECs at 70% conﬂuency
were transfected in six-well plates with siRNAs targeting
human EPOR, VEGFR2, or STAT3 (Life Technologies)
using Lipofectamine 2000 reagent (Life Technologies). A
silencer selective negative control siRNA was used as
control.
For cell proliferation assays, hRMVECs were plated into
96-well plates at a density of 5000 cells per well. At 24
hours after transfection with siRNA, cells were starved in
serum-free medium for 24 hours and then were incubated
with 20 ng/mL VEGFA or control PBS for another 24
hours. To inhibit VEGFR2 or STAT3 activation, cells were
pretreated with 5 mmol/L of the VEGFR2 tryosine-kinase
inhibitor semaxanib (SU5416), 10 mmol/L of the JAK2/
STAT3 inhibitor AG490 (both from Sigma-Aldrich, St.
Louis, MO), or dimethyl sulfoxide (DMSO) vehicle control
for 1 hour before addition of VEGFA. Cell number was
measured with a Vybrant MTT cell proliferation assay kit
(Life Technologies, Carlsbad, CA).
RNA Isolation and qPCR Analysis
Total RNA of cells was extracted by TRI Reagent (Sigma-
Aldrich). For dissected retinas, total RNA was extracted
using an RNeasy mini kit (Qiagen, Valencia, CA). RNA was
quantiﬁed using a NanoDrop spectrophotometer (Thermo
Fisher Scientiﬁc, Waltham, MA). cDNA was generated with
the use of a high-capacity cDNA archive kit (Life Technol-
ogies). qPCR was performed on a Mastercycler ep realplex
system (Eppendorf, Hauppauge, NY) with the use of SYBR
Green master mix (Roche Diagnostics, Indianapolis, IN) and
primers synthesized by the core research facility of the
University of Utah. Expression levels for VEGFA were
normalized to the mean value of internal control b-actin. The
primers (forward and reverse, respectively) were rat EPOR
50-CATTCTCGTCCTCATCTCACTG-30 and 50-AACTC-
ATTCTCTGGGCTTGG-30, and human EPOR 50-CCCCA-
AGTTCGAGAGCAAAG-30 and 50-GGTAGGAGAAGCT-
GTAGTTGC-30.
Protein Extraction and Western Blot Analysis
Dissected retinas and hRMVECs were lysed in radio-
immunoprecipitation assay buffer with 1:100 protease
inhibitors (Roche Diagnostics, Indianapolis, IN) and 2
mmol/L sodium orthovanadate and were homogenized and
centrifuged at 15,700  g for 10 minutes at 4C. Total
protein in the supernatant ﬂuid was quantiﬁed by a bicin-
choninic acid assay (Pierce BCA; Thermo Fisher Scientiﬁc,
Waltham, MA). Membranes were incubated overnight at
4C with primary antibodies to p-STAT3 and total STAT3
(1:1000; Cell Signaling Technology, Danvers, MA),
p-EPOR and total EPOR (1:500; Santa Cruz Biotechnology),1232and p-VEGFR2 and total VEGFR2 (1:500; Santa Cruz
Biotechnology). Blots were visualized, and the relative
densities of bands were calculated as described previously,32
using gel analysis software (UN-SCAN-IT gel, version 6.1;
Silk Scientiﬁc, Orem, UT). Relative activities were calcu-
lated as the ratio of phosphorylated to total protein or to
b-actin and are expressed as fold difference compared with
control. At least six samples from each group were measured
and analyzed.
Statistical Analysis
Signiﬁcant differences between treatment groups were
determined by one-way analysis of variance using the
NewmaneKeuls multiple comparison post hoc test or a
two-way analysis of variance for grouped comparison. A
minimum value of P < 0.05 was considered statistically
signiﬁcant. For proliferation assays, experiments were per-
formed three times with n Z 3 per condition in each
experiment. For qPCR and protein analyses, six individual
samples were used (sometimes pooled from retinas of pups
from the same group).
Results
EPOR Expression and Activation Are Increased in
Retinal Vascular Endothelium in Association with IVNV
in Rat ROP Model
We have previously reported that exogenous EPO restored
developmental retinal vascularization by 40%.32 In addition,
pathological angiogenesis recurred in the rat ROP model
after treatment with anti-VEGFA antibody, in association
with increased retinal EPO.15 These observations suggested
a role for EPO in angiogenesis associated with the ROP
model. To assess EPO signaling, we measured the expres-
sion of retinal EPO and EPOR at several time points,
including phase I (p14) and phase II (p18) in the rat ROP
model and in RA-raised control pups of the same devel-
opmental ages. Compared with RA, EPO protein was
signiﬁcantly decreased in the ROP model at p14 and p18
(Figure 1A); this is in contrast to retinal VEGFA, which is
signiﬁcantly increased at both p14 and p18 in the ROP
model.38 Also, compared with RA, EPOR protein was
signiﬁcantly increased in the ROP model at p14 and p18
(Figure 1B). To determine whether EPOR was activated in
the ROP model, Western blots were performed using
antiep-EPOR antibody. p-EPOR was increased in the retina
in the ROP model at p18, but not at p14, compared with RA
(Figure 1, C and D).
To determine the localization of EPOR activation, cry-
osections from RA and ROP retinas from p18 pups were
colabeled with p-EPOR and lectin to stain vascular cells
and, in adjacent sections, with p-VEGFR2 and lectin. p-
EPOR colabeling with lectin was not strong at p18 in RA
sections, but colabeled vessels were apparent at p18 in theajp.amjpathol.org - The American Journal of Pathology
Figure 1 EPOR expression and activation increased in vascular endothelium in rat ROP model. A and B: Protein analyses for EPO (A) and EPOR (B) in retinas
from rat pups raised in room air (RA) and ROP model pups at time points from baseline to p18. C and D: Representative Western blots of p-EPOR in retina at p14
and p18 (C) and quantiﬁcation of gels (D). E and F: Immunohistochemical staining of p-EPOR (green) (E) or p-VEGFR2 (green) (F) colabeling with lectin (red)
in retinal cryosections at p18. The boxed region in each upper row corresponds to the adjacent image at higher magniﬁcation in the lower row. Negative
controls are shown in Supplemental Figure S1A. Data are expressed as means  SD (A and B) or as individual data points with means  SD (D). *P < 0.05,
**P < 0.01 versus RA at the same developmental age. yyyP < 0.001, overall analysis of variance. Scale bars: 50 mm (E and F, upper rows); 10 mm (E and F,
lower rows). GCL, ganglion cell layer; INL, inner nuclear layer; ONL, outer nuclear layer.
VEGFA Activates EPOR in AngiogenesisROP model (Figure 1E). By contrast, p-VEGFR2 colabeled
with lectin-stained vessels in both RA and ROP sections,
and appeared qualitatively greater in the ROP model
(Figure 1F and Supplemental Figure S1A). Taken together,
these results indicate that, like VEGFR2, EPOR is activated
in ECs in the ROP model during phase II, when IVNV
occurs.
EPOR in ECs Is Up-Regulated and Activated by VEGFA
The oxygen levels used in the ROP model result in retinal
hypoxia, as indicated by increased conjugated pimonidazole
compared with RA.39 Hypoxia induces HIF stabilization,
which allows transcription of angiogenic factors,38 in-
cluding VEGFA40 or EPO.41 In the ROP model, retinal
VEGFA is increased at p14, compared with RA counter-
parts.37 By contrast, EPO protein was decreased during
phase I (p14) (Figure 1A). Because both EPOR and
VEGFR2 were activated in phase II, these ﬁndings raised theThe American Journal of Pathology - ajp.amjpathol.orgquestion of whether activation of EPOR in retinal ECs in the
ROP model is affected by VEGFA. We therefore stimulated
hRMVECswithVEGFA andmeasured EPOR expression and
activation. Compared with PBS control, VEGFA increased
EPOR mRNA expression (Figure 2A) and protein levels
(Figure 2B) after overnight VEGFA treatment. VEGFA
activated VEGFR2, beginning at 5 minutes of treatment
(Supplemental Figure S2, A and B); EPOR activation peaked
at 30 minutes of treatment (Figure 2C and Supplemental
Figure S2, A and C), and STAT3 activation began at 30 mi-
nutes and peaked at 60 minutes of treatment (Supplemental
Figure S2D). We therefore chose 30 minutes of stimulation
with VEGFA for subsequent analyses of VEGFR2, EPOR,
and STAT3 activation in the same cell lysate. Overnight
treatment with 10 IU/mL EPO in hRMVECs also led to an
increase in EPOR protein (Figure 2B), but the induction of
EPOR by EPO was less than with VEGFA treatment;
furthermore, 30 minutes of EPO treatment did not increase
p-EPOR and p-VEGFR2 levels (Supplemental Figure S3).1233
Figure 2 EPOR is up-regulated and activated by VEGFA in vitro and in vivo. A and B: qPCR of human EPOR (A) and Western blots of EPOR protein in hRMVECs
stimulated by 20 ng/mL VEGFA or 10 IU/mL EPO for 18 hours (B). Human b-actin was used as an internal control. C: Western blots of p-EPOR and total EPOR in
hRMVECs stimulated with 20 ng/mL VEGFA or PBS for 30 minutes. D and E: Quantiﬁcation of Western blots of p-VEGFR2 (D) and p-EPOR (E) in retina. F: IHC of
p-VEGFR2 or p-EPOR (blue) colabeled with lectin (red) in retinal sections from rat pups injected with lentivirus-delivered luciferase shRNA (Luc.shRNA) or
VEGFA shRNA (VEGFA.shRNA) at p18 in rat ROP model. Negative controls are shown in Supplemental Figure S1B. Data expressed as means  SD, representative
of three or more independent experiments with n Z 2-3 for each experiment. *P < 0.05 versus control. Scale bar Z 50 mm.
Yang et alOur research group has developed a lentivector gene
therapy strategy to knock down overexpressed VEGFA in
Müller cells in the rat ROP model.36 Retinal VEGFA was
reduced to levels observed in the retina of RA-raised pups,
and VEGFR2 activation was inhibited in vascular ECs, in
association with reduced phase II IVNV.36 To assess whether
knockdown of Müller cellederived VEGFA reduces acti-
vated EPOR in the rat ROP model, we analyzed retinal ly-
sates and retinal sections from p18 rat pup eyes in the ROP
model that were knocked down for Müller cell VEGFA with
a subretinal lentivector-driven shRNA. Compared with the
control luciferase shRNA treatment, knockdown of Müller
cell VEGFA reduced p-VEGFR2 (Figure 2D) in retinal ly-
sates and reduced colabeling of p-VEGFR2 with lectin-
stained ECs in retinal sections (Figure 2F), consistent with
our previous ﬁndings.36 In the same retinas, p-EPOR in
retinal lysates (Figure 2E) and colabeling with lectin in sec-
tions were also signiﬁcantly reduced, compared with the
respective luciferase shRNA controls (Figure 2F and
Supplemental Figure S1B). These ﬁndings provide strong
evidence that inhibiting VEGFA reduces p-VEGFR2 and
p-EPOR in vascular endothelial cells in the ROP model.
Activation of EPOR by VEGFA Enhances
VEGFA-Mediated EC Proliferation
EpoR/ rescued mice were reported to have a signiﬁcant
reduction in ischemia-induced VEGFA and VEGFR21234expression.23 Our results also suggest that crosstalk exists,
but that VEGFAeVEGFR2 signaling can regulate EPOR
expression and activation. To assess crosstalk between
EPOR and VEGFR2, we transfected hRMVECs with EPOR
siRNA or control siRNA and then stimulated them with
VEGFA or PBS (control). EPOR siRNA signiﬁcantly
reduced total EPOR in a dose-dependent pattern (Figure 3A),
achieving maximum reduction at 50 pmol EPOR siRNA; this
dose was used for the later experiments. We then determined
whether knockdown of EPOR affects VEGFA-induced EC
proliferation. Compared with hRMVECs transfected with
control siRNA, VEGFA-induced hRMVEC proliferation
was partially reduced after EPOR siRNA transfection
(Figure 3B). By contrast, inhibition of VEGFR2 by the
VEGFR2 inhibitor SU5416 (Figure 3C) or by siRNA trans-
fection (Figure 3D) abolished VEGFA-induced proliferation.
These results indicate that VEGFA-activated EPOR aug-
ments EC proliferation caused by stimulation with VEGFA,
but that knockdown of EPOR does not fully abolish VEGFA-
induced EC proliferation.
Activation of EPOR Interacts with VEGFR2 to Regulate
STAT3 Activation
One means whereby EPOR can affect VEGFA-induced
angiogenesis is through an interaction between the re-
ceptors. To determine whether there was an interaction be-
tween activated EPORandVEGFR2, coimmunoprecipitationajp.amjpathol.org - The American Journal of Pathology
Figure 3 Knockdown of EPOR reduces VEGFA-induced EC proliferation, and inhibition of VEGFR2 activation inhibits it, in hRMVECs. A: Western blots of total
EPOR in hRMVECs transfected with 0 to 100 pmol EPOR siRNA. BeD: VEGFA-induced proliferation assay in hRMVECs transfected with control siRNA (Con.siRNA)
or EPOR siRNA (B), in hRMVECs treated with SU5416 (C), and in hRMVECs transfected with Con.siRNA or VEGFR2 siRNA (D). Data are expressed as means  SD,
representative of three or more independent experiments. White bars, PBS; black bars, VEGFA (BeD). *P < 0.05, ***P < 0.001.
VEGFA Activates EPOR in Angiogenesisof EPOR andVEGFR2was determined after stimulation with
VEGFA or PBS control. After stimulation with VEGFA, both
p-VEGFR2 and p-EPOR levels increased (Figure 4A),
compared with control, and in the same cell lysate coimmu-
noprecipitation of VEGFR2 and p-EPOR likewise increased
(Figure 4B). Activation of VEGFR2 led to reduced total
VEGFR2 in lysates, which is believed to represent increased
ubiquitinization of VEGFR2 on activation of the receptor.42
To determine whether VEGFR2 activation is required for
the interaction of p-EPOR and VEGFR2, hRMVECs were
pretreated with the VEGFR2 inhibitor SU5416 for 1 hour
before stimulation with VEGFA. SU5416 effectively blocked
VEGFA-induced p-VEGFR2 and also p-EPOR (Figure 4A).
In the same cell lysate, the VEGFA-induced coimmunopre-
cipitation of p-EPOR and VEGFR2 was abolished by pre-
treatment with the SU5416 (Figure 4B). hRMVECs
transfected with EPOR siRNA failed to exhibit VEGFA-
induced phosphorylation of EPOR or an interaction be-
tween p-EPOR and p-VEGFR2 (Figure 4C). These ﬁndings
support the notion that an interaction between the receptors
occurs in response to VEGFA and that activation of either
receptor is needed for the interaction.
Based on the ﬁndings that VEGFA-mediated EC prolif-
eration was augmented through EPOR, we explored
signaling pathways affected by EPOR or VEGFR2 activa-
tion. Previously, we used an ROP model with supplementalFigure 4 VEGFA-activated EPOR interacts with p-VEGFR2 in hRMVECs. A: Weste
with PBS or VEGFA in the presence of DMSO control or SU5416. B and C: Coimmunop
the presence of DMSO control or SU5416 (B) or in hRMVECs transfected with Con.siR
experiments with n Z 2 for each experiment. IB, immunoblot (Western blot); IP
The American Journal of Pathology - ajp.amjpathol.orgoxygen (ROP þ SO model),43 originally developed by Ber-
kowitz and Zhang,44 in which rat pups are placed into 28%
instead of 21% oxygen after repeated ﬂuctuations in oxygen
concentration as a way to study the role of supplemental
oxygen in ROP. We had found that the 28% oxygen reduces
total retinal VEGFA, comparedwith the standard 21%oxygen
model.39 By using the 28% oxygen model, we could unmask
signaling effects dominated byVEGFA-induced signaling and
found that activation of STAT3 was important in phase II
IVNV in the ROP þ SO model.43 In the present study,
therefore, we focused on EC-activated STAT3.
Compared with control siRNA, EPOR siRNA inhibited
VEGFA-induced p-EPOR (Figure 5, A and B) and p-
STAT3 (Figure 5, E and F), and reduced p-VEGFR2
(Figure 5, C and D). Similarly, VEGFA-induced p-
VEGFR2 (Figure 4A), p-EPOR (Figure 4A), and p-STAT3
(Figure 6, A and B) were reduced to baseline in hRMVECs
pretreated with the VEGFR2 inhibitor SU5416. We further
found that knockdown of VEGFR2 by siRNA transfection
inhibited VEGFA-induced p-EPOR (Figure 6, C and E), but
knockdown of STAT3 by siRNA did not affect VEGFA-
induced p-VEGFR2 and p-EPOR (Figure 6, CeE). These
ﬁndings provide evidence that p-VEGFR2 is required for
VEGFA-induced p-EPOR. Furthermore, activation of p-
STAT3 occurred downstream of p-VEGFR2 and p-EPOR.
Inhibition of STAT3 with AG490 reduced VEGFA-inducedrn blots of phosphorylated and total VEGFR2 and EPOR in hRMVECs treated
recipitation of p-EPOR and VEGFR2 in hRMVECs treated with PBS or VEGFA in
NA or EPOR.siRNA (C). Gels are representative of three or more independent
, immunoprecipitation.
1235
Figure 5 Knockdown of EPOR reduces VEGFA-
induced p-VEGFR2 and inhibits VEGFA-induced p-
EPOR and p-STAT3 in hRMVECs. Representative
Western blots, with quantiﬁcation of densitometry,
for p-EPOR (A and B), p-VEGFR2 (C and D), and p-
STAT3 (E and F) in hRMVECs transfected with
Con.siRNA or EPOR.siRNA and treated with PBS or
VEGFA. Data are expressed as means  SD, repre-
sentative of three or more independent experi-
ments with nZ 2 for each experiment. White bars,
PBS; black bars, VEGFA (in panels B, D, and F).
*P < 0.05, **P < 0.01.
Yang et alhRMVEC proliferation to baseline (Figure 6F). Taken
together, these ﬁndings provide evidence that VEGFA ac-
tivates EPOR and induces an interaction between activated
EPOR and VEGFR2, which augments angiogenesis through
activation of STAT3.Discussion
With the present study, we provide evidence that VEGFA
activates VEGFR2, which then phosphorylates EPOR and
forms an interaction with p-EPOR to exacerbate STAT3
activation and mediate the pathological angiogenesis seen in
phase II ROP. We provide data using the relevant ROP
model in rat showing that p-EPORelabeled ECs were
increased during phase II IVNV, but not in phase I.
Furthermore, in the rat model with knockdown for Müller
cell VEGFA, p-EPOR labeling in ECs was signiﬁcantly
reduced, compared with luciferase shRNA control. Knock-
down of EPOR only partially reduced VEGFA-induced EC
proliferation, whereas inhibition of VEGFR2 by either of
two methods (siRNA transfection or tyrosine kinase inhibi-
tion) appeared to reduce VEGFA-induced EC proliferation to
control levels. We further show that VEGFA induced an
interaction between EPOR and VEGFR2, which triggered
activation of STAT3 in ECs to induce EC proliferation. These
ﬁndings suggest that EPOR may enhance VEGFR2 signaling
and thus potentially lead to pathological angiogenesis in1236the setting of increased VEGFA, as in ROP, whereas in the
physiological angiogenesis of normal development, VEGFA
concentration is not as elevated and does not activate EPOR
or cause its interaction with VEGFR2.
Recombinant EPO has been used to treat anemia of pre-
maturity,16 but several studies have indicated an association
between severe ROP and EPO use.28,45 EPO has since been
shown to have other properties besides hematopoiesis,46,47
including neuroprotection through interactions between
EPOR and the b common receptor and angiogenesis in
ischemic limb models through interactions between VEGFR2
and EPOR.19,48 In terms of ROP, inhibition of phase II IVNV
with a neutralizing antibody to VEGFA caused recurrent
pathological angiogenesis in association with increased retinal
EPO expression.15 Studies in the mouse OIR model demon-
strated that EPO is a target for phase II IVNV,30,31 but can be
protective if delivered as an intraperitoneal injection before
hyperoxia-induced vaso-obliteration in phase I.29 Further-
more, prolyl hydroxylase inhibitors can increase EPO and
reduce phase I vaso-obliteration and phase II IVNV in the
mouse OIR49 and rat ROP50 models. Increased size of the
avascular retina has been associated with increased severity of
ROP in several clinical studies,51,52 suggesting that restoring
physiological retinal vascularization and reducing avascular
retina could reduce IVNV in severe ROP. Based on such
studies, it was proposed that the timing of EPO administration
is important and that EPO delivered early might protect against
severe ROP. However, even though exogenous administrationajp.amjpathol.org - The American Journal of Pathology
Figure 6 STAT3 is the downstream target of activated VEGFR2 and EPOR, and activation of STAT3 mediates VEGFA-induced EC proliferation. A and B:
Representative Western blots (A) and quantiﬁcation (B) of p-STAT3 and total STAT3 in hRMVECs treated with PBS or VEGFA in the presence of control DMSO or
SU5416. Quantiﬁcation of densitometry of p-STAT3 is normalized to total STAT3. CeE: Representative Western blots (C) with quantiﬁcation (D and E) of
p-VEGFR2, p-EPOR, total VEGFR2, and total STAT3 in hRMVECs transfected with Con.siRNA, VEGFR2.siRNA, or STAT3.siRNA and treated with PBS or with 20
ng/mL VEGFA for 30 minutes. Quantiﬁcation of densitometry of p-VEGFR2 is normalized to total VEGFR2 (D) and that of p-EPOR is normalized to b-actin (E). F:
Cell proliferation assay in hRMVECs treated with PBS or VEGFA in the presence of DMSO or AG490 Data are expressed as means  SD, representative of three or
more independent experiments with n Z 2 for each experiment. White bars, PBS; black bars, VEGFA (in panels B, D, E and F). *P < 0.05, ***P < 0.001.
VEGFA Activates EPOR in Angiogenesisof EPO restored physiological retinal vascularization in phase I
of the ROP model,32 phase II IVNV was not reduced
(unpublished data). Also, in a multicenter clinical trial of
darbepoietin (a derivative of erythropoietin) delivered sys-
temically by weekly subcutaneous injections beginning
immediately after birth to improve cognitive development in
preterm infants (nZ 102), darbepoietin neither increased nor
reduced the occurrence of severe ROP.33 The study population
was small, but these ﬁndings show that timing of EPO
administration is not the only consideration involved in ROP.Figure 7 The hypothetical signaling pathway in pathological angio-
genesis regulated by interactions of activated VEGFR2 and EPOR. VEGFA
activates VEGFR2, which then phosphorylates EPOR and forms an interac-
tion with p-EPOR to exacerbate STAT3 activation and mediate pathological
angiogenesis as seen in phase II ROP.
The American Journal of Pathology - ajp.amjpathol.orgPrevious studies have indicated a role for EPOR in cancer
cell growth53 and in EPOeEPOR signaling in angiogenesis.54
In EPORknockoutmice rescued by permitting EPO signaling
of hematopoiesis (Epor/ rescued mice), EPOReEPOR
signaling regulated angiogenesis by up-regulating VEGFA
and its receptors in a hindlimb ischemia model, suggesting
crosstalk between the signaling pathways.23,55 In the present
study, we found evidence that VEGFA can also up-regulate
EPOR and activate EPOR through p-VEGFR2, leading to
an interaction between the receptors and pathological angio-
genesis. We previously reported that activation of STAT3
caused phase II IVNV in amodel of ROPþ SO.43Our present
ﬁndings provide evidence that STAT3 is activated in ECs by
VEGFA, leading to IVNV through an interaction between
activated VEGFR2 and EPOR (which accounts for the phase
II IVNV observed previously43). There are several potential
mechanisms whereby STAT3 activation can increase IVNV.
Activated STAT3 dimers can translocate to the nucleus and
regulate transcription of genes involved in angiogenesis by
binding to the gene promoters. In a previous study in the rat
ROP model,32 after repeated oxygen ﬂuctuations, VEGFA
activated STAT3 in Müller cells; after translocation to the
nucleus, p-STAT3 dimers bound the EPO promoter and
down-regulated expression of EPO, in association with
delayed physiological retinal vascular development in phase
I. Thus, VEGFA-activated STAT3 may also be involved in
up-regulating EPOR in ECs by directly binding to the EPOR
promoter.1237
Yang et alOur ﬁndings also support the notion that VEGFA acti-
vates VEGFR2 (which in turn activates EPOR) in phase II
ROP, potentially through another downstream signaling
pathway or through an adaptor protein that facilitates an
interaction between the receptors (Figure 7). Although
current clinical trials show preliminary evidence that ROP is
neither increased nor decreased when EPO derivatives are
administered early,33 the present study does not directly
address whether exogenous EPO can safely be used in
preterm infants. Our ﬁndings provide evidence of a potential
role for EPOR and VEGFR2 interactions, induced by
VEGFA in phase II IVNV in ROP and in other conditions
associated with pathological angiogenesis.
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